Taiwan Radiology Congress 2026

Coreline at TRC 2026: Advancing ILD & COPD Analysis with Aview 2.0

What is Aview 2.0?

Aview 2.0 is an AI-powered platform that enables quantitative CT analysis of lung diseases, including interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD), within a single integrated workflow.
At the Taiwan Radiology Congress 2026, Coreline Soft will showcase how Aview 2.0 expands beyond detection into a comprehensive respiratory analysis platform.
 

Why ILD and COPD Matter Now

With the expansion of LDCT screening, the clinical focus is shifting from detection to disease characterization and monitoring.
• ILD requires consistent fibrosis assessment
• COPD requires structural and functional evaluation
This shift is driving demand for quantitative imaging tools.
 

 

From Detection to Quantification

Aview 2.0 supports this transition by enabling:
• Quantitative analysis of lung patterns in ILD
• Imaging biomarker assessment in COPD
• Standardized evaluation across time and readers
 Moving beyond visual interpretation toward data-driven assessment.

 

Built for Real Clinical Workflow

Aview 2.0 is designed to fit into real radiology workflows:
• Unified summary view of all findings
• Integrated reporting across modules
• Faster navigation and loading speed
Enabling efficient interpretation without disrupting reading flow.

 

One CT, Multiple Insights

A single CT scan can provide:
• Lung nodule detection
• ILD quantification
• COPD analysis
• Cardiovascular insights
Supporting screening, diagnosis, and follow-up in one platform.

 

See Aview 2.0 at TRC 2026

Coreline Soft will showcase how Aview 2.0 enables quantitative lung analysis and workflow integration at TRC 2026.
Visit us at Booth No.C05 to experience Aview 2.0 in action.